It is young white males who are dying from drug overdoses in the U.S., according to a New York Times analysis of death certificates.
It is young white males who are dying from drug overdoses in the U.S., according to a New York Timesanalysis of death certificates.
Read next: FDA: Final guidance on evaluation, labeling of abuse-deterrent opioids
“The rising death rates for those young white adults, ages 25 to 34, make them the first generation since the Vietnam War years of the mid-1960s to experience higher death rates in early adulthood than the generation that preceded it,” according to the article.
The newspaper analyzed nearly 60 million death certificates collected by the Centers for Disease Control and Prevention from 1990 to 2014 and found that, overall, death rates for non-Hispanic whites either increased or stayed the same for all the adult age groups under aged 65. During the same time period, death rates for blacks and most Hispanic groups continued to decline.
Read next: FDA panel green lights Probuphine for opioid addiction
The death rates linked to drug overdoses – both illegal and prescription drugs – are alarming. In 2014, the overdose death rate for white people ages 25 to 34 was 5 times its level in 1999, and the rate for 35- to 44-year-old whites tripled during the same time period, according to The New York Times.
“That is startling. Those are tremendous increases,” Dr. Wilson Compton, deputy director of the National Institute on Drug Abuse, told the newspaper.
In addition, the death rates for drug overdoses and suicides in white males “are running counter to those of chronic diseases,” like heart disease, Ian Rockett, an epidemiologist at West Virginia University, told the newspaper.
The death rate among young whites rose faster for the less educated – by 23% for those without a high school education – compared with only 4% for those with a college degree or more.
Read next: Intranasal naloxone has potential to be first in US to treat opioid overdose
Navitus to Offer Unbranded Stelara Biosimilar, Remove Stelara from Formulary
March 13th 2025Lumicera Health Services, Navitus’ specialty pharmacy, has made a deal with Teva to offer an unbranded biosimilar that they estimate will save $112,000 and $336,000 per patient per year. Navitus will remove Stelara from formulary on July 1, 2025.
Read More
FDA Approves Neffy 1 mg Nasal Spray for Pediatric Patients
March 6th 2025Neffy 1 mg is now approved by the FDA to treat pediatric patients who weigh 33 to 65 lbs. Neffy was first FDA-approved as a 2 mg dose in August 2024 for the emergency treatment of anaphylaxis in children and adults weighing at least 66 lbs.
Read More